Financial Health Assessment: Teemans Limited (02977697)

Patient profile: A 31-year-old specialist manufacturer of under-pressure pipeline fittings (split tees, line stopping and hot tapping equipment) serving the oil & gas sector. Family-owned (Craig and Xxxxxx Xxxxxxxxname shown to subscribers hold 100% between them), small company regime, audit-exempt, clean filing record with no overdue accounts or confirmation statements.

1. Financial Health Score: A− (Very Healthy)

Teemans presents as a financially robust business with an exceptionally consistent track record: net assets have grown in nine of the last ten years, quadrupling from £487k (2016) to £1.98m (2025) — a compound growth rate of roughly 17% per annum. The only blemish was a modest £25k dip in the COVID-affected 2020 year, after which growth immediately resumed. The company is now effectively free of long-term debt, holds its highest cash balance on record, and has tripled its working capital cushion year-on-year.

The grade is held back from a full "A" by three watch points: a sharp build-up in debtors and stock, declining fixed asset investment, and the limited visibility that comes with filleted, audit-exempt accounts (no P&L on public file, so turnover and margins cannot be independently verified).

2. Key Vital Signs

Interpretation of the pulse: The balance sheet shows a business generating and retaining real profits year after year. Retained earnings of £1.98m against just £100 of share capital tell the story plainly — this company has built its strength entirely from its own operations rather than external injection of funds.

3. Symptoms Analysis

Positive symptoms: - Consistent profitability across a decade, including through COVID-19 and the 2022–23 inflation shock — evidence of pricing power and a resilient niche (pipeline maintenance is non-discretionary safety-critical spend for operators). - Deleveraged balance sheet: long-term creditors eliminated and hire purchase largely cleared. - Clean compliance record: accounts approved and filed within deadline, no overdue filings, no director disqualifications, active status throughout. - Provisions reduced (£290k → £260k), suggesting liabilities crystallising as expected rather than deteriorating.

Symptoms warranting monitoring (amber flags): - Debtors nearly doubled (£416k → £763k, +83%) and now represent 60% of current assets. Combined with stock rising 49% (£138k → £206k) and creditors rising 52%, this pattern is consistent with a step-up in trading activity — growth absorbing working capital — rather than distress (cash rose sharply at the same time, which distress would not produce). However, without turnover figures, debtor days cannot be calculated, and a single large slow-paying customer could be hiding in that number. - Fixed assets are shrinking (£2.02m → £1.90m, −6%), meaning depreciation is outpacing capital expenditure. For a manufacturer, persistent underinvestment in plant and machinery can quietly erode productive capacity and quality — the corporate equivalent of muscle loss despite a healthy weight. - Concentration risks: a two-person officer structure creates key-person dependency, and the customer base is tied to oil & gas infrastructure — a sector with long-term energy-transition headwinds even though maintenance demand is durable.

4. Diagnosis

A financially fit, self-funding business in its prime, with early signs of growth-related working-capital strain and mild investment undernourishment.

The company's financial physiology is sound: strong equity heart, healthy cash circulation, no debt burden, and a ten-year record of profitable trading that very few small manufacturers can match. The current picture is one of controlled expansion — rising debtors, stock and creditors moving together alongside rising cash — rather than any pathology. The main vulnerabilities are structural (sector and key-person concentration) rather than financial.

Prognosis: Positive. On current indicators, Teemans has substantial reserves to absorb shocks, fund investment, or weather a downturn in its end markets. The principal risk to the outlook is not insolvency but gradual competitive decline if fixed-asset reinvestment continues to lag depreciation.

5. Recommendations (Prescription for Continued Wellness)

1. Take a working-capital reading monthly. Implement aged-debtor reporting and credit checks on the large balances driving the £763k debtor figure; consider tightening terms or using invoice finance selectively if any single customer exceeds ~25% of the total.
2. Resume preventative capital investment. Set a capex budget at least equal to annual depreciation (~£120k+) to halt the erosion of the fixed asset base and protect manufacturing capability.
3. Build a cash buffer target. Cash of £303k covers only ~32% of current liabilities; a target of 3–6 months of operating costs would provide a stronger immune system against a delayed customer payment.
4. Reduce key-person dependency. Document critical processes, consider succession planning and key-person insurance given the two-officer structure.
5. Diversify the patient base where possible. Explore adjacent markets (water utilities, hydrogen/carbon-capture pipelines) to reduce reliance on traditional oil & gas capex cycles.
6. Consider voluntary disclosure. Publishing turnover and profit figures (even while audit-exempt) would strengthen credibility with lenders, insurers and larger customers conducting supplier due diligence.

Names of the people mentioned are shown to subscribers. See subscription